PharmaCyte Biotech
PMCB
PMCB
26 hedge funds and large institutions have $8.68M invested in PharmaCyte Biotech in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
10.02% more ownership
Funds ownership: 6.74% → 16.75% (+10%)
26% less call options, than puts
Call options by funds: $226K | Put options by funds: $305K
Holders
26
Holding in Top 10
–
Calls
$226K
Puts
$305K
Top Buyers
| 1 | +$1.62M | |
| 2 | +$1.53M | |
| 3 | +$647K | |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$519K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$484K |
Top Sellers
| 1 | -$145K | |
| 2 | -$139K | |
| 3 | -$118K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$19.8K |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$11.9K |